Trial data ends where the hardest questions begin. Dr. Garrido-Castro tackles the highest-stakes clinical dilemmas: sequencing Trop−2 ADCs vs. PARP inhibitors for BRCA patients, the urgent unmet need in CNS disease, and the essential role of biomarkers-tissue/liquid biopsy in overcoming resistance.
A forward-looking view at where the field must go.
Biomarkers and Resistance: Interpreting Trop-2 ADC Performance in Diverse mTNBC Patient Subsets
You may also like
Recommended Videos
